Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

NCT07209410 ↗

Phase 4 Recruiting 35 enrolled Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.

Timeline

Start: 2025-11-01
Primary completion: 2026-12-15
Completion: 2027-06-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brimonidine	Small molecule	0.025 %	Other

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

Summary

Timeline

Drugs

Indications